Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Sickle Cell Diseases Treatment Market Size, Share, Growth, Trends, and Industry Analysis: By Disease Type, By Therapy, By Drug Class, Others), By End User, and Region
Sickle Cell Disease Treatment Market size was valued at US$ 3.6 billion in 2023 and is poised to grow at a CAGR of 14.09% from 2024-2030. Drastic reduction of total RBC count is called as anaemia. It is also defined as the inability of carrying the appropriate amounts of oxygen by blood. Sickle cell diseases are the type of blood disorders which are genetically inherited. Sickle-cell anaemia is the common type of SCD in which sickle-shaped cell is formed. Generally, sickle cell disease starts taking shape at the early age i.e., within a year after birth which leads to several health issues like attacks of pain which are also called as the sickle-cell crisis, limbs swelling, bacterial infections etc. Chronic pain can be developed along with the age. Sickle-cell diseases arise when an individual inherited by abnormal copies of Hg gene from each parent.
Burgeoning prevalence of sickle cell disease has expected to drive the market. As per Centre for Disease Control and Prevention, in 2016, about 100,000 individuals in U.S. are affected by the sickle cell diseases. Black or the African Americans are commonly more susceptible to sickle cell diseases. One in thirteen babies who belongs to the black race are born with SCDs. Researchers have moved ahead to treat SCD by antibiotics to genome level. Researchers from the Stanford School of Medicine corrected the genes successfully which are carrying a gene for SCD and transplanted them with the healthy cells. With the help of Clustered Regularly Interspaced Short Palindromic Repeat technique (CRISPR), researchers have replaced the SCD cell genes with one which doesnt carry those genes.
Study Period
2024-2030Base Year
2023CAGR
14.09%Largest Market
Asia-PacificFastest Growing Market
North America
Sickle Cell Diseases Treatment Market is driven by the increasing prevalence of sickle cell anaemia in the developed, developing as well as underdeveloped economies. In addition to this unmet needs are highly available, a rise in product pipelines for the treatment of SCD is anticipated to pose great demand for the market. Sickle cell disease treatment market is propelled by rising support by the regulatory bodies and government in the form of investments, fast-track approvals for the discovery of newer treatments. Sickle cell anaemia treatment market is restrained by slow adoption of treatments due to the cost associated with it, the absence of a permanent cure for this disease and complications associated with treatment.
Report Benchmarks |
Details |
Report Study Period |
2024-2030 |
Market Size in 2023 |
US$ 3.6 billion |
Market CAGR |
14.09% |
By Disease Type |
|
By Therapy |
|
By Drug Class |
|
By End User |
|
Download Free Sample Report
The global sickle cell diseases treatment market size was valued at US$ 3.6 billion in 2023 and is projected to grow at a CAGR of 14.09% from 2024 to 2030.
Increasing Prevalence of Sickle Cell Disease
North America is the fastest-growing for sickle cell diseases treatment market
1.Executive Summary |
2.Global Sickle Cell Diseases Treatment Market Introduction |
2.1.Global Sickle Cell Diseases Treatment Market - Taxonomy |
2.2.Global Sickle Cell Diseases Treatment Market - Definitions |
2.2.1.Disease Type |
2.2.2.Therapy |
2.2.3.Drug Class |
2.2.4.Region |
3.Global Sickle Cell Diseases Treatment Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Product Landscape |
3.6. New Product Launches |
3.7. Impact of COVID 19 on Market |
4.Global Sickle Cell Diseases Treatment Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5.Global Sickle Cell Diseases Treatment Market By Disease Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
5.1. Sickle Beta Thalassemia |
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Sickle Haemoglobin C Disease |
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. Sickle Cell Anaemia |
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
5.4. Others |
5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.4.3. Market Opportunity Analysis |
6.Global Sickle Cell Diseases Treatment Market By Therapy, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
6.1. Bone Marrow Transplant |
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Blood Transfusion |
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Gene Therapy |
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
7.Global Sickle Cell Diseases Treatment Market By Drug Class, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
7.1. Antibiotics |
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Analgesics |
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Antimetabolite (Hydroxyurea) |
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
7.4. Others |
7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.4.3. Market Opportunity Analysis |
8.Global Sickle Cell Diseases Treatment Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
8.1. North America |
8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Europe |
8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. Asia Pacific (APAC) |
8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
8.4. Middle East and Africa (MEA) |
8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.4.3. Market Opportunity Analysis |
8.5. Latin America |
8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.5.3. Market Opportunity Analysis |
9.North America Sickle Cell Diseases Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
9.1. Disease Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.1.1.Sickle Beta Thalassemia |
9.1.2.Sickle Haemoglobin C Disease |
9.1.3.Sickle Cell Anaemia |
9.1.4.Others |
9.2. Therapy Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.2.1.Bone Marrow Transplant |
9.2.2.Blood Transfusion |
9.2.3.Gene Therapy |
9.3. Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.3.1.Antibiotics |
9.3.2.Analgesics |
9.3.3.Antimetabolite (Hydroxyurea) |
9.3.4.Others |
9.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.4.1.United States of America (USA) |
9.4.2.Canada |
10.Europe Sickle Cell Diseases Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
10.1. Disease Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.1.1.Sickle Beta Thalassemia |
10.1.2.Sickle Haemoglobin C Disease |
10.1.3.Sickle Cell Anaemia |
10.1.4.Others |
10.2. Therapy Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.2.1.Bone Marrow Transplant |
10.2.2.Blood Transfusion |
10.2.3.Gene Therapy |
10.3. Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.3.1.Antibiotics |
10.3.2.Analgesics |
10.3.3.Antimetabolite (Hydroxyurea) |
10.3.4.Others |
10.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.4.1.Germany |
10.4.2.France |
10.4.3.Italy |
10.4.4.United Kingdom (UK) |
10.4.5.Spain |
11.Asia Pacific (APAC) Sickle Cell Diseases Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
11.1. Disease Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.1.1.Sickle Beta Thalassemia |
11.1.2.Sickle Haemoglobin C Disease |
11.1.3.Sickle Cell Anaemia |
11.1.4.Others |
11.2. Therapy Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.2.1.Bone Marrow Transplant |
11.2.2.Blood Transfusion |
11.2.3.Gene Therapy |
11.3. Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.3.1.Antibiotics |
11.3.2.Analgesics |
11.3.3.Antimetabolite (Hydroxyurea) |
11.3.4.Others |
11.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.4.1.China |
11.4.2.India |
11.4.3.Australia and New Zealand (ANZ) |
11.4.4.Japan |
11.4.5.Rest of APAC |
12.Middle East and Africa (MEA) Sickle Cell Diseases Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
12.1. Disease Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.1.1.Sickle Beta Thalassemia |
12.1.2.Sickle Haemoglobin C Disease |
12.1.3.Sickle Cell Anaemia |
12.1.4.Others |
12.2. Therapy Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.2.1.Bone Marrow Transplant |
12.2.2.Blood Transfusion |
12.2.3.Gene Therapy |
12.3. Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.3.1.Antibiotics |
12.3.2.Analgesics |
12.3.3.Antimetabolite (Hydroxyurea) |
12.3.4.Others |
12.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.4.1.GCC Countries |
12.4.2.South Africa |
12.4.3.Rest of MEA |
13.Latin America Sickle Cell Diseases Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
13.1. Disease Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.1.1.Sickle Beta Thalassemia |
13.1.2.Sickle Haemoglobin C Disease |
13.1.3.Sickle Cell Anaemia |
13.1.4.Others |
13.2. Therapy Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.2.1.Bone Marrow Transplant |
13.2.2.Blood Transfusion |
13.2.3.Gene Therapy |
13.3. Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.3.1.Antibiotics |
13.3.2.Analgesics |
13.3.3.Antimetabolite (Hydroxyurea) |
13.3.4.Others |
13.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.4.1.Brazil |
13.4.2.Mexico |
13.4.3.Rest of LA |
14. Competition Landscape |
14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
14.2.1.Biogen |
14.2.2.Gamida Cell |
14.2.3.Genetix Pharmaceuticals Inc. |
14.2.4.Sangamo Biosciences |
14.2.5.Alnylam Pharmaceuticals, Inc. |
14.2.6.Acceleron Pharma |
14.2.7.Global Blood Therapeutics Inc. |
14.2.8.Emmaus Medical, Inc. |
14.2.9.Novartis AG |
14.2.10.Bristol-Myers Squibb Company |
15. Research Methodology |
16. Appendix and Abbreviations |
Key Market Players